9th International Neoantigen Summit 2026 Park Plaza Victoria Amsterdam, Amsterdam

The neoantigen-targeted therapies industry is thawing and coming out of its biotech winter fuelled by Moderna’s recent news showing 49% decrease in disease progression after 5 years. This momentum has reignited confidence across pharma and biotech, accelerating a neoantigen programme and pushing more candidates into the clinic than ever before.

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen therapies.

In a unique position to unite all the key players in the neoantigen industry, including the likes of Nykode Therapeutics, Evaxion, Geneos and more, this summit sits at the heart of the neoantigen industry, making every conversation relevant and every connection intentional.

Attend your only annual checkpoint to access the latest clinical updates, uncover breakthrough innovations and form partnerships that will drive the next wave of neoantigen-targeted therapies forward.